UK guidance for the treatment of people with Alzheimer’s disease remains unchanged
Wednesday 26 August 2009
The UK’s National Institute for Health and Clinical Excellence (NICE) have upheld their original conclusion that the drugs donepezil, galantamine, rivastigmine and memantine be recommended for use only by people with moderate Alzheimer’s disease. This decision follows consultation with stakeholders on the economic model which underpinned NICE’s 2006 guidance on the use of drugs to treat Alzheimer’s disease.
For further information please see